key: cord-0916089-8c8ush41
authors: Chao, Chieh‐Ju; DeValeria, Patrick A.; Sen, Ayan; M.Sc,; Lee, Hong; Pedrotty, Dawn M; Patel, Bhavesh; Arsanjani, Reza; Naqvi, Tasneem Z.
title: Reversible cardiac dysfunction in severe COVID‐19 infection, mechanisms and case report
date: 2020-08-27
journal: Echocardiography
DOI: 10.1111/echo.14807
sha: 4f40aca4124a778688d1dae85e6933c5d094cfe6
doc_id: 916089
cord_uid: 8c8ush41

A previously healthy 49‐year‐old male patient presented with COVID‐19 infection and required mechanical ventilation and extracorporeal membrane oxygenation due to severe hypoxemia. Echocardiography showed cardiac dysfunction with an apical sparing strain pattern, which rapidly normalized within a week. Apical sparing myocardial strain in patients with COVID‐19 infection may suggest reverse‐type stress cardiomyopathy.

The novel COVID-19 mainly attacks the respiratory system; however, the involvement of other end organs is common in critically ill patients. The most common symptoms of COVID-19 infection are fever and cough, and 15% of patients may eventually require intensive care. 1 Myocardial injury or infarction, myocarditis, congestive heart failure, arrhythmias, and cardiogenic shock have been reported with COVID-19 infection. [2] [3] [4] Among all patients with COVID- 19 , myocardial injury was reported in more than 7% and 23% in critically ill patients. 5 Although the exact mechanism of cardiac involvement in COVID-19 remains unclear, the possible pathogenesis is believed to be related to direct cardiac involvement through the ACE2 signaling pathway. 6, 7 Increased secretion of ACE2 in patients with underlying cardiovascular diseases may also explain the significantly increased risk of death in this group of patients. 8, 9 Microvascular dysfunction, demand ischemia, plaque rupture, or cytokine storm triggered by an imbalanced response to type 1 and type 2 T helper cells are other potential mechanisms of cardiac injury. Given that ACE2 is also found on vascular endothelial cells, infection-medicated vasculitis is also possible. 10 Cytokine and inflammatory mediators can result in arterial inflammation, which could result in coronary plaque rupture. However, no reports yet associate SARS-CoV-2 with acute coronary syndrome (ACS). A case of presumably acute myocarditis due to COVID-19 infection described LV apical hypokinesis, 11 and the other two cases reported decreased LVEF. 12, 13 Apical-type stress-induced cardiomyopathy was recently reported as a possible presentation of COVID-19-related cardiac involvement. 14 Herein, we discuss another potential presentation of cardiac injury in COVID 19 infection that occurred in a previously healthy patient who became critically ill with COVID-19 infection.

A previously healthy 49-year-old male patient presented to a local emergency department with fever, cough, and pneumonia, and Figure 1B) . The initial chest X-ray revealed severe diffuse bilateral pulmonary infiltrates consistent with ARDS ( Figure 2A ). Central venous O2 saturation was 79%.

Laboratory data showed initial: troponin 526 ng/L, creatinine kinase 506 U/L, NT-proBNP 4,573 pg/mL, ferritin 3601 mcg/L, C-reactive protein 104.9 mg/L (<8 mg/L), IL-6 > 400 pg/mL (<1.8 pg/mL), creatinine 0.83 mg/dL, total bilirubin 1.5 mg/dL, AST 124 U/L, ALT 55 U/L, procalcitonin 6.28 ng/mL, and lactate 3 mmol/L. The initial TTE at our hospital showed mild to moderately reduced LVEF of 40% with marked hypokinesis of basal and mid segments and F I G U R E 1 Baseline and follow-up ECGs. Panel A. The initial ECG showed sinus tachycardia, narrow QRS, QTc interval of 467 ms, and T-wave inversion in the precordial leads V1-V3, I and aVL. Panel B. Three days later, a repeat ECG showed right bundle branch block, QTc of 539 ms, and mild diffuse ST elevation preserved wall motion of apical segments ( Figure 2B and Video S1).

was −13.2% (normal ≥ negative than −18%) with preserved apical strain ( Figure 2C ).

Mixed venous saturation was not consistent with a diagnosis of cardiogenic shock. Vasopressin and norepinephrine were infused to maintain adequate mean arterial pressure for refractory hypotension from vasodilatory shock. Broad-spectrum antibiotics were started for possible pneumonia. The patient received two doses of Tocilizumab for signs and biomarkers suggestive of cytokine release syndrome. Hydroxychloroquine and azithromycin were administered initially, however, discontinued after 2 days due to QTc prolongation ( Figure 1B) .

The patient was continued on V-V ECMO, mechanical ventilation, and antibiotics, and his oxygen requirements progressively decreased to FiO2 40%, TV 200-300 mL, and PEEP 10 cmH2O.

Troponin had decreased to 41 ng/L, ferritin to 788 mcg/L, C-reactive protein to 6.5 mg/L (<8 mg/L), and IL-6 to 181 pg/mL (normal < 1.8 pg/mL).

Six days later, infiltrates started resolving on the chest X-ray ( Figure 2D) , and a follow-up TTE showed normalization of LVEF to 55% and marked improvement in regional wall motion abnormalities ( Figure 2E and Video S2). LV GLS normalized to −19.8%

( Figure 2F ). The patient's pulmonary status continued to improve, tracheostomy was performed on day 10, and the patient was decannulated from V-V ECMO on day 12. He remained culture negative.

In this case, LV wall motion abnormalities in a noncoronary distribution followed by rapid normalization of wall motion do not suggest ACS and are most consistent with reverse type of stress cardiomyopathy involving basal and mid-LV segments as opposed to apical LV segments in the classical type of stress or Takotsubo cardiomyopathy. A recent report also described a typical takotsubo presentation in a COVID-19-infected patient who required V-A ECMO support 14 ;

a recent case series further reported a prevalence of stress cardiomyopathy of 4.2% in male COVID-19 patients. 15 Perhaps, the most compelling mechanism of myocardial injury in our patient is secondary to cytokine storm and a hyperinflammatory state that occurred Table 1 . Apical stress cardiomyopathy has been reported but reverse stress cardiomyopathy has not been reported thus far.

Myocardial inflammation and myocarditis can be detected by endomyocardial biopsy or by magnetic resonance imaging, which may show a variable pattern of Gadolinium enhancement. 16 Our patient did not undergo magnetic resonance imaging or endomyocardial biopsy, as these tests were not feasible in this critically ill patient. The markedly elevated troponin upon presentation, development of marked conduction abnormality, and diffuse appearing mild ST elevation on follow-up ECG may be suggestive of myopericarditis with apical sparing possibly from reduced apical distribution of myocardial ACE 2 receptors. However, rapid cardiac recovery without steroids is highly unusual in myocardial inflammation or infection. The apical sparing LV strain distribution pattern in our patient is commonly seen in cardiac amyloidosis and nonischemic cardiomyopathy, 17 and has not been described in viral myocarditis. 18 While apical hypokinesis or ballooning is the most common echo finding in stress cardiomyopathy, 14 basal or mid segmental variant of stress cardiomyopathy 19 is not infrequent and is associated with basal to mid segmental hypokinesis with preserved apical wall motion and apical strain, 20 mild ST elevation, QT prolongation, T-wave inversion, and rapid recovery of LV function-all present in our patient. It is interesting to note that recovery of LV systolic function, although associated with improvement in pulmonary status, occurred prior to the complete resolution of ARDS. Cytokine storm and sympathetic surge that occurred early in the course of our patient's illness were the likely triggers of stress cardiomyopathy and marked troponin elevation. 10 Improvement in cardiac function in our patient followed the administration of Tocilizumab, which is an IL-6 inhibitor, improves cytokine release syndrome, and has also been reported to be effective in ARDS in a prior study. 21 The effectiveness of Tocilizumab in treating COVID-19-related acute myocarditis is unclear. 21 Cases from China reported complete recovery of fulminant myocarditis treated with glucocorticoid and human immunoglobulin. 12, 13 We did not need to use either of those therapies. Since Azithromycin and Hydroxychloroquine were given for a short period, and no steroids were administered, these likely did not contribute to the cardio-pulmonary recovery. 

There are no relevant disclosures or conflicts of interest for this work by any of the authors. 

Clinical characteristics of coronavirus disease 2019 in China

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic

Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease

COVID-19 and the cardiovascular system

SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies

Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin

First case of COVID-19 complicated with fulminant myocarditis: a case report and insights

Takotsubo Syndrome in the Setting of COVID-19 Infection

Takotsubo Cardiomyopathy in Males with Covid-19

Cardiac Magnetic Resonance Assessment of Myocarditis

Myocardial Deformation Pattern Differs between Ischemic and Non-ischemic Dilated Cardiomyopathy: The Diagnostic Value of Longitudinal Strains

Longitudinal strain bull's eye plot patterns in patients with cardiomyopathy and concentric left ventricular hypertrophy

Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy

Inverted Takotsubo cardiomyopathy and the fundamental diagnostic role of echocardiography

Tocilizumab treatment in COVID-19: a single center experience